Integrated Clinical Systems, Inc. Opens European Office in Switzerland
New Jersey-based Integrated Clinical Systems, Inc. announced the opening of a European branch office in Lausanne, Switzerland.
New Jersey-based Integrated Clinical Systems, Inc. (ICS), developers of Integrated Review™ & JReview®, clinical review and analysis software tools, announced the opening of a European branch office in Lausanne, Switzerland. The office will be the company’s first location in Europe, dedicated to client management and business development in Europe, Middle East & Africa (EMEA).
With 40% of its customer base located in Europe, the company felt that the regional presence and support was a good move for current customers, as well for achieving a greater footprint in the EMEA regions.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
